PROCEPT BioRobotics Corporation Announces Cigna Adds Aquablation Therapy to its Coverage Policy

PROCEPT® BioRobotics Corporation (PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced a new positive coverage decision from Cigna, expanding access to Aquablation therapy for the treatment of their members with Benign Prostatic Hyperplasia. The revised policy is effective September 15, 2021.

Recommended AI News: Pure IP Named Partner for Operator Connect for Microsoft Teams General Availability (GA) Release

Cigna Corporation is a global health service company that provides health insurance coverage for approximately 16 million members in the United States. Their mission is to improve the health, well-being, and peace of mind to those they serve by making health care simple, affordable, and predictable.

“We are pleased with Cigna’s decision to cover Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to BPH. This coverage update will provide access to an effective, safe and durable treatment option to millions of members nationwide,” said Reza Zadno, President and CEO of Procept BioRobotics. “Payors continue to rely on high quality clinical data when establishing coverage criteria for new treatments, Aquablation therapy is the only BPH surgical treatment with proven clinical outcomes, independent of the size or the shape of the prostate, and a reduced risk of sexual side effects. With this updated policy, Cigna joins Medicare and numerous private health plans that cover Aquablation therapy.”

Recommended AI News: N.E.W. AI Tool Launched by Consumer Fusion Leads the Future of Reputation Management

[To share your insights with us, please write to sghosh@martechseries.com ]